Biotech Values

[ThomasS]

MNTA: "...could they be setting up for business as usual a la pre-2010?"
Impossible. Folks seem to have lost sight of the fact that MNTA still gets a substantial amount of revenue from M-Enox going forward even if Teva ever gets approval. (A large if). Certainly not the huge wad of current cash, but a substantial annual amount (let's call it $50M) nonetheless under the royalty arrangement. However, Teva has to get that approval and win the infringement case.
All the while awaiting the next game-changer... Copaxone, M118, FoB partnerships, etc.